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multivariate analysis. The reporting pathologist was not 
found to be predictive of PSMs (P = 0.855).
Conclusion We showed that the reporting pathologist 
does not influence T2 positive margin status, in contrast 
to tumour characteristics and surgeon experience. T2 posi-
tive margin assessment therefore appears to be an objective 
quality outcome measure.
Keywords Radical prostatectomy · Outcomes 
assessment · Prostate cancer · Positive margins · 
Laparoscopic surgery
Introduction
The gold standard measure of surgeon performance for 
radical prostatectomy would include patient reported 
outcomes such as continence, quality of life with PSA 
follow-ups; however, this is rarely practical in the clini-
cal setting. There is therefore a need for a more easily 
attainable, unbiased marker of surgical performance. We 
recently showed that T2 positive margin rate is the most 
informative quality outcome measure with the least poten-
tial observer bias [1]. This highlights the possible use of 
T2 positive margin rates as a single objective outcome 
measure indicative of surgeon skill. Positive surgical 
margins (PSMs) have been studied in depth to analyse 
their clinical implications following radical prostatec-
tomy (RP). Stephenson et al. conducted a study looking 
at 11,521 patients who underwent a RP between 1987 
and 2005 and found no association between margin sta-
tus and cancer-specific mortality within 15 years post-RP. 
However, they did observe a positive association with bio-
chemical recurrence, so that it is recommended to avoid 
PSMs where possible [2].
Abstract 
Objective To assess potential biases, such as the report-
ing pathologist, that may affect objectivity of T2 positive 
margin rates as a quality outcome measure following radi-
cal prostatectomy.
Patients and methods Prospective data on 183 consecu-
tive LRP patients with pT2 disease, operated on by a sin-
gle surgeon (2003–2009), were studied. Outcomes were 
grouped as pre-, peri-, and post-operative and included: 
age, ethnicity, Gleason score, reporting pathologist, per-
centage of positive cores, operative time, blood loss, nerve-
sparing status, hospital stay and prostate weight. Descrip-
tive analysis and logistic regression analysis were carried 
out to compare these variables by positive margin status.
Results A total of 30 (16.4 %) positive surgical margins 
(PSMs) were reported. Surgical stage, earlier date of sur-
gery, and lower prostatic weight showed statistically sig-
nificant associations with PSM status in both univariate and 
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Intra-prostatic incision (IPI) is associated with signifi-
cantly increased biochemical recurrence (BCR), compared 
to patients with negative surgical margins with or without 
extra-prostatic extension. The 5-year biochemical recur-
rence-free survival was only 77 % for patients with intra-
prostatic incision, compared to 94 % for those without 
(P ≤ 0.0001), according to Preston et al. [3]. Similar results 
have also been shown in other studies [4, 5]. There is thus a 
growing body of evidence to support PSMs as a prognostic 
factor indicative of biochemical recurrence following RP.
In addition to its value as a diagnostic predictor, PSM 
have been suggested to be a good indicator of surgeons’ per-
formance. Vickers et al. [6] showed that surgeons who per-
formed higher volumes of RP showed a decrease in PSMs 
over time, with a plateau after 250 procedures—suggesting 
that PSM rates can be used to monitor surgeons’ experi-
ence. Although this data were published for the open proce-
dure, laparoscopic procedures have a similar learning curve 
as shown by Secin et al. [7] who showed a similar learning 
curve plateauing after 200–250 cases. Whilst pathological 
factors have been shown to influence margin status, surgeon 
skill and experience also may play an important role. East-
ham et al. [8] showed that high-volume surgeons had sig-
nificantly lower PSM rates. It has been suggested that intra-
prostatic incision may be a better quality measure of surgeon 
experience than PSM rates [9]. However, rates of intra-pro-
static incisions vary greatly between studies. This is poten-
tially due to the difficulty in differentiating between true T2 
positive margins and extra-prostatic extension [9–11].
We have therefore evaluated the clinical variables that 
may affect T2 PSMs to determine whether this can be used 
as an objective measurement of surgeon skill and experience.
Methodology
Study population
We obtained prospective data for 183 consecutive patients 
who underwent laparoscopic radical prostatectomy (LRP) 
between 2003 and 2009. A single surgeon carried out all 
procedures. The surgeon reported all data pre-, peri- and 
post-operatively. All data were also verified in the electronic 
medical records. Only patients with T2 stage disease as 
classified by TNM staging [12] were included in the study.
Margin status
Information on margin status was collected post-operatively. 
A PSM was reported when cancer cells were seen touching 
or extending beyond the inked resection margin, and were 
all identified in one Pathology Department by 10 different 
consultant pathologists, using standard procedures. PSM 
location was described as apical, circumferential or both. 
The pathologists are all dedicated consultant uropathologists 
employed in a teaching hospital. Inter-pathologist review of 
specimens is carried out as part of an internal-audit.
Clinical variables
Pre-operative, peri-operative, and post-operative variables 
were studied in relation to margin status.
Pre-operative variables included age at surgery, ethnic-
ity, Gleason Score (primary and secondary), TNM staging, 
PSA, and percentage positive cores. Age at surgery was 
categorised into ≤60 and >60 as older age is an important 
clinical determinant of prostate cancer [13]. Total Gleason 
score was divided into three categories (≤6, 7, ≥8) [14], 
which corresponded to different survival profiles [15]. PSA 
was divided into categories of ≤10 and >10 ng/ml. The per-
centage of positive cores was studied as a categorical varia-
ble (<25 %, 25–49 %, ≥50 %). Date of surgery was studied 
as a categorical variable (2003–2004, 2005–2006, 2007–
2009), as a measure of increasing surgeon experience.
Peri-operative variables were reported by the surgeon 
and included operative time, blood loss and neurovascular 
bundle (NVB) resection status. NVB status was assessed 
as no NVB, unilateral and bilateral NVB. Operative time 
(minutes) was measured as the time from the first incision 
to the last suture. Blood loss (ml) was recorded from the 
suction system in theatre.
Post-operative variables studied included prostate 
weight as reported by the pathologists. Length of hospital 
stay (days) obtained from the medical record.
Statistical analysis
Statistical analysis was carried out using Statistical Analy-
sis Systems (SAS) release 9.4 (SAS Institute, Cary, NC).
Univariable logistic regression analysis was performed 
for each clinical variable to assess their associations with 
margin status. A test for trend was conducted by assigning 
categories as an ordinal scale. To further assess this asso-
ciation while adjusting for potential confounding factors, 
multivariable analysis was performed by incorporating all 
clinical variables in the model. Finally, to assess any dif-
ferences by margin location only in patients with PSM 
(n = 30), one-way ANOVA and Chi-square tests were per-
formed for each clinical variable with respect to the three 
margin locations (apical, circumferential or both).
Results
Descriptive statistics of the patient cohort for pre-oper-
ative variables are presented in Table 1, with peri- and 
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post-operative variables in Table 2. 53 % of patients were 
>60 years of age at time of surgery. The majority was of 
a white background and presented with PSA ≤10 ng/ml 
(77 %), with a Gleason score of ≤6 (60 %). NVB resection 
was performed unilaterally in 29 patients (16 %) and bilat-
erally in 68 (37 %). Mean hospital stay was 2 days. 49.7 % 
of procedures were carried out between 2007 and 2009, 
when the surgeon was more experienced. 
Surgical stage showed a statistically significant cor-
relation with PSM status in both univariate (P = 0.035) 
(Table 3) and multivariate analysis (P = 0.004) (Table 4). 
Patients with higher surgical stage of T2b and T2c were 
more likely to have PSMs (OR 8.7 (95 % CI 1.07–70.71) 
and OR 4.1 (95 % CI 0.52–33.27), respectively) than those 
with T2a disease. Earlier date of surgery was statistically 
significantly associated with higher PSM rates in both 
univariate (Table 3) and multivariate analysis (Table 4) 
(P = 0.018). PSMs were also most prevalent in patients 
with prostatic weight between 20 and 59 g. PSMs were not 
associated with the reporting pathologist (P = 0.855).
In contrast with the univariate analysis, larger prostatic 
weight (>100 g) showed a higher predictive value for PSM 
in multivariate analysis (Table 4). Multivariable analysis 
also showed NVB resection status to be associated with 
PSMs, with more PSM in patients in whom NVB resection 
was not attempted (P = 0.037).
Finally, we assessed whether any of the clinical vari-
ables studied were differentially distributed across PSM 
locations (Table 5). Highest mean blood loss was observed 
in multifocal PSMs (apex and circumferential) (883.3 ml, 
P = 0.006). Patients with apical PSMs mostly had T2c 
disease, whereas those with circumferential PSMs had the 
highest proportion of T2b disease (P = 0.01).
Discussion
Our multivariate analyses showed that several clinical vari-
ables are predictive of T2 PSMs, including nerve-sparing 
Table 1  Descriptive statistics for pre-operative variables
Frequency/mean %/SD
Pre-operative variables
Age at surgery (years)
 ≤60 86 47.3
 >60 96 52.7
Date of surgery
 2003–2004 44 24.0
 2005–2006 48 26.2
 2007–2009 91 49.7
Ethnicity
 Black 37 20.2
 White 134 73.2
 Other 3 1.6
 Missing 9 4.9
PSA (ng/ml)
 ≤10 141 77.0
 >10 40 21.9
 Missing 2 1.3
Percentage cores positive (%)
 <25 % 55 30.1
 25–49 % 56 30.1
 ≥50 % 38 20.8
 Missing 34 18.6
Table 2  Descriptive statistics for peri, and post-operative variables
Peri-operative variables
Mean blood loss (ml) 279 225
Mean operative time (min) 159 37
Nerve-sparing status
 None 38 20.8
 Unilateral 29 15.8
 Bilateral 68 37.2
 Missing 48 26.2
Post-operative variables
Mean hospital stay (days) 2 2.12
Prostate weight (g)
 20–59 100 54.6
 60–99 49 26.8
 ≥100 13 7.1
Missing 21 11.5
Pathologist
 1 67 36.6
 2 7 3.8
 3 10 5.5
 4 53 29
 5 9 4.9
 6 1 0.5
 7 11 6.0
 8 1 0.5
 9 5 2.7
 10 4 2.2
Missing 15 8.2
Surgical stage
 T2a 30 16.4
 T2b 52 28.4
 T2c 96 52.5
 T2x 5 2.7
Total Gleason
 ≤6 109 59.6
 7 60 32.8
 ≥8 13 7.1
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Table 3  Univariate analysis of pre, peri and post-operative variables
Positive surgical margin 
(N = 30)
Negative surgical margins 
(N = 153)
Odds ratio 95 % Confidence interval Ptrend
Pre-operative variables
Age at surgery (years) 0.057
 ≤60 19 (22 %) 67 (78 %) 1 Ref
 >60 11 (11 %) 85 (89 %) 0.46 0.20–1.02
Date of surgery 0.011
 2003–2004 13 (30 %) 31 (70 %) 1 Ref
 2005–2006 7 (15 %) 41 (85 %) 0.41 0.15–1.14
 2007–2009 10 (11 %) 81 (89 %) 0.29 0.12–0.74
Ethnicity 0.052
 Black 9 28 1 Ref
 White 21 113 0.58 0.24–1.40
 Other + missing 0 12 n/a n/a
PSA (ng/ml) (SD) 0.093
 ≤10 27 114 1 Ref
 >10 3 37 0.34 0.10–1.19
Percentage cores positive (%) 0.720
 <25 % 8 (15 %) 47 (85 %) 1 Ref
 25–49 % 10 (18 %) 46 (82 %) 1.28 0.46–3.52
 ≥50 % 8 (21 %) 30 (79 %) 1.57 0.53–4.62
 Missing 4 30 0.78 0.22–2.83
Peri-operative variables
Mean blood loss (mls) (SD) 299.8 (363.7) 274.8 (185.4) 1.00 0.99–1.00 0.580
Mean operative time (min) (SD) 160.8 (39.06) 158.0 (37.1) 1.00 0.99–1.01 0.708
Nerve-sparing status 0.219
 None 9 29 1 Ref
 Unilateral 4 25 0.52 0.14–1.88
 Bilateral 11 57 0.62 0.23–1.67
 Missing 6 42 0.46 0.23–3.47
Post-operative variables
Mean Hospital stay (days) (SD) 2.07 (1.2) 2.02 (2.26) 1.01 0.84–1.21 0.911
Prostate Weight (g) 0.035
 20–59 24 (24 %) 76 (76 %) 1 Ref
 60–99 3 (5 %) 46 (95 %) 0.21 0.06–0.72
 ≥100 2 (15 %) 11 (85 %) 0.58 0.12–2.78
 Missing 1 20 0.16 0.02–1.24
Pathologist 0.855
 1 10 57 1 Ref
 2 4 3 7.60 1.47–39.21
 3 1 9 0.63 0.07–5.56
 4 11 42 1.49 0.58–3.84
 5 0 9 n/a n/a
 6 0 1 n/a n/a
 7 3 8 2.14 0.48–9.46
 8 0 1 n/a n/a
 9 1 4 1.43 0.14–14.10
 10 0 4 n/a n/a
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status and tumour characteristics. Fewer PSM were seen 
with later date of surgery, confirming the notion of a surgi-
cal learning curve in RP procedures. The reporting patholo-
gist and Gleason score were not associated with T2 positive 
margin status.
PSMs have been extensively studied to determine their 
clinical significance. Several studies have outlined the 
prognostic value of PSMs [2, 10, 16–20]. It is clear that 
while PSMs are not strongly linked to cancer-specific 
survival, PSMs are an important predictor of BCR. For 
these reasons, PSM rates are increasingly being reported 
as a quality measure, indicating superior surgeon experi-
ence and skill. However, few studies to date have investi-
gated factors that may influence margin status apart from 
surgical experience and tumour characteristics. Although 
we limited our analysis to patients with pT2 stage, we 
assessed several clinical variables predictive of prostate 
cancer prognosis including, pre-operative PSA and Glea-
son score.
Surgeon experience has a large impact on PSM rate. 
Vickers et al. [21] showed that PSM rates were signifi-
cantly improved when treated by a surgeon who had com-
pleted at least 250 procedures compared to a surgeon who 
had completed only 10. Our study has also shown this to 
be the case. Patients who underwent a RP between 2007 
and 2009 had a lower PSM rate, compared to those in 
2005–2006 (OR 0.312 vs OR 0.417). This was also true 
of patients undergoing surgery in 2005–2006 compared to 
those in 2003–2004 (OR 0.417 vs OR 1). The British Asso-
ciation of Urological Surgeons (BAUS) recently published 
surgeon reported data regarding transfusion, length of stay 
and complication rates across the UK but positive margin 
rates were not published [22]. The current study includes 
margin data and shows a clear link between surgeon expe-
rience and positive margin rates T2 disease. The surgeon 
in our study has had extensive training for the laparoscopic 
procedure. He undertook some assisting as a trainee and 
did part procedure cases as a primary surgeon. In addition 
he underwent 7 months of fellowship training in Institute 
Montsouris, Paris, which involved assisting, and gaining 
dry and wet laboratory training.
Our study only included T2 disease and therefore looked 
at the impact of surgical stage on PSMs on a finer basis. We 
showed a significant association between T2 PSMs and sur-
gical stage between subclasses in T2 disease (T2 a, b and 
c). Increasing tumour volume makes incision of the pros-
tate more likely in T2 disease.
Lower prostatic weight has also been shown to be an 
independent predictor of IPI due to the surgical difficulty 
involved in removing a small gland. [9, 23–25]. Marchetti 
et al. (2011) [25] found that predicted probability of a 
PSM was 22 % for patients with <25 g prostates, which 
decreased to just 1 % for those with >150 g prostates. Our 
study also showed lower prostatic weight (20–59 g) to be 
a predictor of T2 PSMs in the univariate analysis. In mul-
tivariate analysis, prostates >100 g had highest PSM rates. 
Patients with large prostates constituted a small number of 
more difficult cases and hence resulted in higher positive 
margin rates. Higher blood loss was associated with mul-
tifocal PSMs (P = 0.006). Higher blood loss is a surrogate 
for surgical difficulty and hence makes surgical incision of 
the prostate more likely.
PSMs have also been associated with nerve-sparing sta-
tus. Due to the close approximation of the NVBs to the 
posterolateral prostate gland, this is the most common site 
for iatrogenic IPI [4, 5, 9, 10, 26]. Here, NVB status was 
not associated with margin location in the multivariable 
analysis, contradicting the literature [27]. Patients who did 
not undergo NVB sparing procedures had higher incidence 
of PSMs than those with nerve-sparing procedures. Non-
nerve-sparing surgery was more likely in high-volume T2 
disease. High-volume disease in the non-nerve spare group 
makes prostatic incision more likely (apex and base) and 
can explain why higher PSM rates were seen in this group 
Table 3  continued
Positive surgical margin 
(N = 30)
Negative surgical margins 
(N = 153)
Odds ratio 95 % Confidence interval Ptrend
Surgical stage (%) 0.035
 T2a 1 29 1 Ref
 T2b 12 40 8.70 1.07–70.71
 T2c 12 84 4.14 0.52–33.27
 T2x 5 0 n/a n/a
Total Gleason 0.187
 ≤6 22 87 1 Ref
 7 6 54 0.44 0.17–1.15
 ≥8 2 11 0.72 0.15–3.48
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of patients. A limit to our study was that information on 
the grade of nerve spare (partial, inter-fascial, intra-fascial) 
was not available as this may have an impact on the risk of 
PSMs.
IPI refers to iatrogenic incision into the prostate that 
contains cancer. There is great variability in the rates of IPI 
reported by different studies. For example, several studies 
have found incidence of IPI to be 1.8–2.8 % [9, 11, 28]. 
However, some studies have reported rates of IPI as high 
as 20 % [29]. Indeed, in our study, 30 patients (16.4 %) 
presented with PSMs in T2 disease (IPI). One possible 
explanation is difficulty in pathologic interpretation of sur-
gical margin status, as has been highlighted by a number of 
studies [9–11]. There is a recognised danger for over-call-
ing PSMs because of difficulty in differentiating between 
extraprostatic extension (EPE) and IPI [10]. Despite 
recently published guidelines on standardised handling of 
RP specimens by the International Society of Urological 
Pathology (ISUP) (2009), there is still a lack of consistency 
in the reporting of surgical margins [30].
A study by van der Kwast et al. [31]. highlights the 
inter-observer variation in the reporting of positive margin 
status. External review of pathology reports was carried 
out for patients in the European Organisation for Research 
and Treatment of Cancer trial (EORTC). There was only a 
57.5 % agreement for extra-prostatic extension, and 69.4 % 
concordance for surgical margin status. A total of 24.9 % of 
the cases that were called positive at the local hospital were 
subsequently called negative on review in the study. More 
recent evidence has contradicted these findings, showing 
agreement in over 87 % of cases regarding margin status 
[32].
This evidence supports the fact that pathologists may 
interpret PSMs differently and calls into question the objec-
tivity of surgical margin status as a quality measure. How-
ever, in our study, we found no such correlation between 
the reporting pathologist and margin status in both univari-
ate and multivariate analysis. Therefore, it seems unlikely 
that the reporting pathologist has an impact on T2 PSM 
rates reported by different surgeons. It is more likely that 
any differences between T2 PSM rates reported by differ-
ent surgeons are down to surgical experience, and tumour 
characteristics, not external bias.
One of the particular strengths of this study was the 
use of data from a single surgeon. This removes the het-
erogeneity of surgeon skills and allows valid compari-
sons of PSM rate over time. Only 30 PSMs were present 
in our study and therefore reduced the statistical power of 
our analysis. However, our PSM rate was comparable with 
Table 4  Multivariate analysis of pre, peri, and post-operative 
variables
Multivariable
OR 95 % CI Ptrend
Pre-operative variables
Age at surgery (years) 0.042
 ≤60 1 Ref
 >60 0.24 0.06-0.95
Date of surgery 0.018
 2003–2004 1 Ref
 2005–2006 0.44 0.04–5.22
 2007–2009 0.31 0.03–3.62
Ethnicity 0.070
 Black 1 Ref
 White 0.71 0.19–2.70
 Other + missing n/a n/a n/a
PSA (ng/ml) 0.131
 ≤10 1 Ref
 >10 0.29 0.06–1.45
Percentage cores positive (%) 0.898
 <25 % 1 Ref
 25–49 % 1.57 0.32–7.62
 ≥50 % 1.83 0.38–8.84
 Missing 0.97 0.13–7.19
Peri-operative variables
Blood loss (mls) 1.00 0.99–1.00 0.576
Op time (min) 0.99 0.97–1.01 0.458
Nerve-sparing status 0.037
 None 1 Ref
 Unilateral 0.24 0.03–1.72
 Bilateral 0.19 0.04–1.00
 Missing 0.17 0.03–1.01
Post-operative variables
Surgical stage 0.004
 T2a 1 Ref
 T2b 6.52 0.63–67.01
 T2c 7.52 0.50–113.26
 T2x n/a n/a
Prostate weight (g) 0.031
 20–59 1 Ref
 60–99 0.35 0.08–1.52
 ≥100 1.29 0.13–12.96
 Missing 0.16 0.02–1.64
Total Gleason 0.148
 ≤6 1 Ref
 7 0.18 0.04–0.90
 ≥8 0.63 0.08–4.84
Mean hospital stay (days) 0.88 0.63–1.21 0.427
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Table 5  Analysis of variables by positive margin location
Apex (%) N = 15 Circumferential (%) N = 12 Apex and circumferential (%) N = 3 P value
Age at time of surgery (years) 0.898
 ≤60 10 (62.5) 7 (58.3) 2 (66.7)
 >60 5 (31.3) 5 (41.7) 1 (33.3)
 Missing 1 (6.3) 0 (0.0) 0 (0.0)
Ethnicity 0.924
 Black 4 (26.7) 4 (33.3) 1 (33.3)
 White 11 (73.3) 8 (66.7) 2 (66.7)
 Other 0 (0) 0 (0) 0 (0)
Mean PSA (ng/ml) 0.189
 ≤10 12 (80.0) 12 (100) 3 (100)
 >10 3 (20.0) 0 (0) 0 (0)
Mean percentage cores positive (%) 0.057
 <25 % 0 (0) 7 (58.3) 1 (33.3)
 25–49 % 7 (46.7) 2 (16.7) 1 (33.3)
 >50 % 5 (33.3) 2 (16.7) 1 (33.3)
 Missing 3 (20.0) 1 (8.3) 0 (0)
Mean blood loss (mls) (SD) 182.33 (87.7) 300.83 (237.2) 883.33 (970.0) 0.006
Mean operative time (min) (SD) 153 (34.4) 170.83 (45.9) 160 (34.6) 0.515
Mean hospital stay (days) (SD) 2.27 (1.3) 1.67 (0.7) 2.67 (2.1) 0.297
Mean prostate weight (g) 0.442
 20–59 12 (80.0) 10 (83.3) 2 (66.7)
 60–99 2 (13.3) 1 (8.3) 0 (0.0)
 ≥100 0 (0.0) 1 (8.3) 1 (33.3)
 Missing 1 (6.7) 0 (0.0) 0 (0.0)
Pathologist 0.144
 1 7 (30.4) 3 (15.8) 0 (0.0)
 2 1 (4.3) 2 (10.5) 1 (33.3)
 3 0 (0.0) 1 (5.3) 0 (0.0)
 4 5 (21.7) 5 (26.3) 1 (33.3)
 5 0 (0.0) 0 (0.0) 0 (0.0)
 6 0 (0.0) 0 (0.0) 0 (0.0)
 7 2 (8.7) 1 (5.3) 0 (0.0)
 8 0 (0.0) 0 (0.0) 0 (0.0)
 9 0 (0.0) 0 (0.0) 1 (33.3)
 10 0 (0.0) 0 (0.0) 0 (0.0)
 Missing = 15 8 (34.8) 7 (36.8) 0 (0.0)
Nerve-sparing status 0.535
 None 3 (20.0) 5 (41.7) 1 (33.3)
 Unilateral 2 (13.3) 1 (8.3) 1 (33.3)
 Bilateral 5 (33.3) 5 (41.7) 1 (33.3)
 Missing 5 (33.3) 1 (8.3) 0 (0.0)
Surgical stage 0.010
 T2a 0 (0.0) 0 (0.0) 1 (33.3)
 T2b 4 (26.7) 8 (66.7) 0 (0.0)
 T2c 9 (60.0) 2 (16.7) 1 (33.3)
 T2x 2 (13.3) 2 (16.7) 1 (33.3)
Total Gleason 0.626
 ″6 10 (62.5) 10 (83.3) 2 (66.7)
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other studies of a similar nature, for example Kumano et al. 
(2009) [29], suggesting that the population was representa-
tive. Another limitation of the current study was that data 
were missing for many of the patients in our database. This 
was particularly the case for nerve-sparing status. In our 
study, 48 patients (26.2 %) were missing data on nerve-
sparing status. Of these 6 had a PSM at surgery, which rep-
resents 20 % of the PSMs in our population. This may be 
one reason why our study contradicted the majority of the 
literature with regard to the association of NVB resection 
and PSMs. Time to surgery was not evaluated in our cohort 
and would be interesting to study in the future, as waiting 
time may lead to tumour growth and therefore higher risk 
of PSM than is predicted by the clinical variables.
Conclusion
In the absence of good patient reported outcomes, T2 posi-
tive margin rates are increasingly being used a quality out-
come measure of surgeon experience. Our study has shown 
that T2 positive margin rates are not influenced by exter-
nal biases such as the reporting pathologist but are affected 
by tumour characteristics and surgeon skill alone and can 
therefore be considered as an objective measure of surgeon 
skill.
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